The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Open accessAbstract
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical immunoregulatory molecule (expressed on activated T cells and a subset of regulatory T cells) capable of down-regulating T cell activation. Blockade of CTLA-4 has been shown in animal models to improve the effectiveness of cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v. administration of a fully human anti-CTLA-4 antibody (MDX-010) in conjunction with s.c. vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). This blockade of CTLA-4 induced grade III/IV autoimmune manifestations in six patients (43%), including dermatitis, enterocolitis, hepatitis, and hypophysitis, and mediated objective cancer regression in three patients (21%; two complete and one partial responses). This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The anti-CTLA-4 blocking antibody ipilimumab was the first immune checkpoint inhibitor to be tested and approved for the treatment of cancer patients (19, 20).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [20]
Citations
Cites
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
A cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786
Self-citationA Theory of Self-Nonself Discrimination
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307
Research works printed but not linked: 4
- Alegre, M. L., Frauwirth, K. A. & Thompson, C. B. (2002) Nat. Rev. Immunol. 1, 220-228.
- Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M., Burg, M. B. & Allison, J. P. (2000) Cancer Res. 60, 2444-2448.10811122
- Pass, H. A., Schwarz, S. L., Wunderlich, J. R. & Rosenberg, S. A. (1998) Cancer J. Sci. Am. 4, 316-323.9815296
- Angelini, G., Gardella, S., Ardy, M., Ciriolo, M. R., Filomeni, G., Di Trapani, G., Clarke, F., Sitia, R. & Rubartelli, A. (2002) Proc. Natl. Acad. Sci. USA 99, 1471-1476.
Cited by
Sorted by citations
Items 801–900 of 1,000
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823261db · Cited by 26
Checkpoint blockade: the end of the beginning
Wolchok, J. D. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00617-9 · Cited by 26
Tumor Immune Escape Mechanisms that Operate During Metastasis
Croci, D. O., & Salatino, M. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798376987 · Cited by 26
Gogas, H. J., Dafni, U. G., Koon, H. B., Spyropoulou‐Vlachou, M., Metaxas, Y., Buchbinder, E. I., Pectasides, E., Tsoutsos, D. A., Polyzos, A., Stratigos, A., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-108 · Cited by 26
Mechanisms of T-cell inhibition: implications for cancer immunotherapy
Mittendorf, E. A., & Sharma, P. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.144 · Cited by 26
Immune Microenvironment in Colorectal Cancer: A New Hallmark to Change Old Paradigms
de la Cruz‐Merino, L., Henao, F., Baz, D. V., Fernández, E. N., Zoilo, J. J. R., de Villena, M. C. M., & Pulido, E. G. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/174149 · Cited by 26
Long, P., Zhang, Q., Xue, M., Cao, G., Li, C., Chen, W., Jin, F., Li, Z., Li, R., Wang, X., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108886 · Cited by 26
Hu, A., Ding, M., Zhu, J., Liu, J.-Q., Pan, X. J., Ghoshal, K., & Bai, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00210 · Cited by 26
Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
Шубникова, Е. В., Букатина, Т. М., Velts, N. Y., Kaperko, D. A., & Кутехова, Г. В. (2020) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2020-8-1-9-22 · Cited by 26
Targeted therapies in melanoma
Queirolo, P., & Acquati, M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.07.009 · Cited by 26
Inhibitory costimulation and anti-tumor immunity
Martín‐Orozco, N., & Dong, C. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.003 · Cited by 26
Wolchok, J. D., & Saenger, Y. M. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32801497c6 · Cited by 26
McNeel, D. G. (2007) · Current Opinion in Urology · doi:10.1097/mou.0b013e3280eb10eb · Cited by 26
Vaccination: role in metastatic melanoma
Pilla, L., Valenti, R., Marrari, A., Patuzzo, R., Santinami, M., Parmiani, G., & Rivoltini, L. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.8.1305 · Cited by 26
Regulatory T Cells in Human Ovarian Cancer
Peng, D.-J., Liu, R., & Zou, W. (2012) · Journal of Oncology · doi:10.1155/2012/345164 · Cited by 27
Schlereth, S. L., Refaian, N., Iden, S., Cursiefen, C., & Heindl, L. M. (2014) · BioMed Research International · doi:10.1155/2014/639058 · Cited by 25
Kee, D., & McArthur, G. A. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.014 · Cited by 26
Immune System Efficiency in Cancer and the Microbiota Influence
Barbosa, A. M., Gomes-Gonçalves, A., Castro, A. G., & Torrado, E. (2021) · Pathobiology · doi:10.1159/000512326 · Cited by 25
Obesity-induced thymic involution and cancer risk
Lagou, M. K., & Karagiannis, G. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.008 · Cited by 26
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
Kejamurthy, P., & Devi, K. T. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02267-4 · Cited by 28
Cblb -deficient T cells are less susceptible to PD-L1-mediated inhibition
Peer, S., Baier, G., & Gruber, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18360 · Cited by 26
Abozeid, M., Rosato, A., & Sommaggio, R. (2017) · BioMed Research International · doi:10.1155/2017/5791262 · Cited by 25
Drug Delivery for Cancer Immunotherapy and Vaccines
Batty, C. J., Tiet, P., Bachelder, E. M., & Ainslie, K. M. (2018) · Pharmaceutical Nanotechnology · doi:10.2174/2211738506666180918122337 · Cited by 25
Motofei, I. G. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000573 · Cited by 25
BiovaxID™: a personalized therapeutic cancer vaccine for non-Hodgkin’s lymphoma
Lee, S., Jiang, Y.-F., Park, K. U., Woo, A. F., & Neelapu, S. S. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.113 · Cited by 25
Scott, C. T. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1037 · Cited by 25
He, J., Wang, J., Wang, D., Dai, S., Yv, T., Chen, P., Ma, R., Diao, C., & Lv, G. (2014) · Endocrine · doi:10.1007/s12020-013-0050-8 · Cited by 24
Major therapeutic developments and current challenges in advanced melanoma
Sullivan, R. J., & Flaherty, K. T. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12698 · Cited by 24
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
Rajani, K. R., & Vile, R. G. (2015) · Viruses · doi:10.3390/v7112914 · Cited by 25
Gorczynski, R. M., & Zhu, F. (2017) · Cancer Management and Research · doi:10.2147/cmar.s147326 · Cited by 24
Recent and current clinical trials in canine appendicular osteosarcoma.
Poon, A. C., Matsuyama, A., & Mutsaers, A. J. (2020) · PubMed Central · Cited by 24
Matsuya, T., Nakamura, Y., Matsushita, S., Tanaka, R., Teramoto, Y., Asami, Y., Uehara, J., Aoki, M., Yamamura, K., Nakamura, Y., et al. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15345 · Cited by 24
The Immunotherapy Revolution in Kidney Cancer Treatment
Hasanov, E., Gao, J., & Tannir, N. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000471 · Cited by 24
Ipilimumab: an investigational immunotherapy for glioblastoma
Youssef, G., & Dietrich, J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1826436 · Cited by 24
Recent Advances in the Role of Arid5a in Immune Diseases and Cancer
Nyati, K. K., & Kishimoto, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.827611 · Cited by 25
Histopathology of Gastrointestinal Immune-related Adverse Events
Zhang, M. L., & Deshpande, V. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001730 · Cited by 24
Lepland, A., Malfanti, A., Haljasorg, U., Asciutto, E. K., Pickholz, M., Bringas, M., Đorđević, S., Salumäe, L., Peterson, P., Teesalu, T., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0043 · Cited by 25
Hinz, T., Buchholz, C. J., van der Stappen, T., Cichutek, K., & Kalinke, U. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211305.98244.56 · Cited by 24
Tartz, S., Kamanová, J., Simsova, M., Šebo, P., Bolte, S., Heussler, V. T., Fleischer, B., & Jacobs, T. (2006) · Infection and Immunity · doi:10.1128/iai.74.4.2277-2285.2006 · Cited by 24
Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
Foley, K. C., Nishimura, M. I., & Moore, T. V. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000436 · Cited by 24
Aragon‐Sanabria, V., Kim, G. B., & Dong, C. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-95294-9_7 · Cited by 24
Advances in tumour immunotherapy.
King, J., Waxman, J., & Stauss, H. J. (2008) · QJM : monthly journal of the Association of Physicians · doi:10.1093/qjmed/hcn050 · Cited by 26
Curiel, T. J. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9914-6_9 · Cited by 24
Vacca, C., Fallarino, F., Perruccio, K., Orabona, C., Bianchi, R., Gizzi, S., Velardi, A., Fioretti, M. C., Puccetti, P., & Grohmann, U. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.03.030 · Cited by 24
Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers
Page, D. B., Yuan, J. D., & Wolchok, J. D. (2010) · Immunotherapy · doi:10.2217/imt.10.21 · Cited by 23
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists
Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23
Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
Re, V. D., Caggiari, L., Repetto, O., Mussolin, L., & Mascarin, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101596 · Cited by 23
A twenty year perspective on melanoma therapy
Flaherty, K. T. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13125 · Cited by 23
Sabado, R. L., Meseck, M. L., & Bhardwaj, N. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_44 · Cited by 24
Sabel, M. S., Hess, S. D., Egilmez, N. K., Conway, T. F., Chen, F.-A., & Bankert, R. B. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0668-3 · Cited by 23
New Roads Open Up for Implementing Immunotherapy in Mesothelioma
Cornelissen, R., Heuvers, M. E., Maat, A. P. W. M., Hendriks, R. W., Hoogsteden, H. C., Aerts, J. G. J. V., & Hegmans, J. P. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/927240 · Cited by 23
Miguel, A., Sendra, L., Noé, V., Ciudad, C. J., Dası́, F., Hervás, D., Herrero, M. J., & Aliño, S. F. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s104393 · Cited by 23
Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies
Chang, S. T., Menias, C. O., Lubner, M. G., Mellnick, V. M., Hara, A. K., & Desser, T. S. (2017) · Radiographics · doi:10.1148/rg.2017160162 · Cited by 23
p110δ PI3K as a therapeutic target of solid tumours
Xenou, L., & Papakonstanti, E. A. (2020) · Clinical Science · doi:10.1042/cs20190772 · Cited by 23
Prospects of Controlling Breast Cancer Metastasis by Immune Intervention
Fulton, A. M., Miller, F. W., Weise, A. M., & Wei, W. (2007) · Breast Disease · doi:10.3233/bd-2007-26110 · Cited by 23
Vaccination therapy in prostate cancer
Marrari, A., Iero, M., Pilla, L., Villa, S., Salvioni, R., Valdagni, R., Parmiani, G., & Rivoltini, L. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0233-8 · Cited by 23
Tumor-Associated Antigens and Biomarkers in Cancer and Immune Therapy
Malyankar, U. M. (2007) · International Reviews of Immunology · doi:10.1080/08830180701402496 · Cited by 23
Cruz, J. S. D., Morrison, S. L., & Penichet, M. L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.041 · Cited by 23
Srivastava, P., Rütter, M., Antoniraj, G. M., Ventura, Y., & David, A. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c12821 · Cited by 22
Effective effectors: How T cells access and infiltrate the central nervous system
Congdon, K. L., Sanchez-Perez, L. A., & Sampson, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.007 · Cited by 22
Novel therapeutics for melanoma
Seetharamu, N., Ott, P. A., & Pavlick, A. C. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.40 · Cited by 22
Autoimmune hypophysitis: expanding the differential diagnosis to CTLA-4 blockade
Gutenberg, A., Landek‐Salgado, M. A., Tzou, S., Lupi, I., Geis, A. L., Kimura, H. J., & Caturegli, P. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.37 · Cited by 22
Demystifying Immunotherapy in Prostate Cancer
Madan, R. A., Gulley, J. L., & Kantoff, P. W. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31828160a9 · Cited by 22
Lehrer, S. P., & Rheinstein, P. H. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514545478 · Cited by 22
RNA as performance-enhancers for dendritic cells
Boczkowski, D., & Nair, S. K. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003614749 · Cited by 22
Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells
Hofman, F. M., Stathopoulos, A., Kruse, C. A., Chen, T. C., & Schijns, V. E. J. C. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611009060462 · Cited by 22
Improved Anti-Treg Vaccination Targeting Foxp3 Efficiently Decreases Regulatory T Cells in Mice
Mousavi-Niri, N., Memarnejadian, A., Pilehvar‐Soltanahmadi, Y., Sadeghi, M. A., Mahdavi, M., Kheshtchin, N., Arab, S., Namdar, A., Jadidi, F., Zarghami, N., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000133 · Cited by 22
Immunotherapy of gynecological cancers
Matanes, E., & Gotlieb, W. H. (2019) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2019.03.005 · Cited by 22
Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22
Robert, C., & Mateus, C. (2011) · médecine/sciences · doi:10.1051/medsci/20112710013 · Cited by 22
Montag, D. T., & Lotze, M. T. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.013 · Cited by 22
Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Hahn, T., Polanczyk, M. J., Borodovsky, A., Ramanathapuram, L. V., Akporiaye, E. T., & Ralph, S. J. (2013) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201011314030010 · Cited by 22
Dendritic cell vaccine strategies for renal cell carcinoma
Schendel, D. J. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.2.221 · Cited by 22
Peptide vaccine trials for melanoma: preclinical background and clinical results
Talebi, T. N., & Weber, J. S. (2003) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.007 · Cited by 22
Farzaneh, L., Kasahara, N., & Farzaneh, F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0189-8 · Cited by 22
Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions
Page, D. B., Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0337-1 · Cited by 22
Use of ipilimumab in the treatment of melanoma
Jeter, J., & Acharya, U. H. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s45884 · Cited by 21
Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music, M., Prassas, I., & Diamandis, E. P. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1499706 · Cited by 21
Luo, H., Wang, W., Mai, J., Yin, R., Cai, X., & Li, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267918 · Cited by 22
Long Peptide Vaccination Can Lead to Lethality through CD4+ T Cell-Mediated Cytokine Storm
Kitamura, H., Sedlik, C., Jacquet, A., Zaragoza, B., Dusséaux, M., Prémel, V., Sastre‐Garau, X., & Lantz, O. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000933 · Cited by 21
D’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 21
NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer
Bai, R., Yuan, C., Sun, W., Zhang, J., Luo, Y., Gao, Y., Li, Y., Gong, Y. Q., & Xie, C. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59019 · Cited by 22
RetractedMovva, S., & Verschraegen, C. F. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802643347 · Cited by 21
Improving T cell therapy for cancer
Foster, A. E., & Rooney, C. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.215 · Cited by 22
Goff, S. L., Robbins, P. F., El‐Gamil, M., & Rosenberg, S. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181affbf0 · Cited by 21
Self-citationKlyushnenkova, E., Riabov, V., Kouiavskaia, D. V., Wietsma, A. C., Zhan, M., & Alexander, R. B. (2014) · The Prostate · doi:10.1002/pros.22858 · Cited by 20
IFN‐γ‐induced PD‐L1 expression on human melanocytes is impaired in vitiligo
Willemsen, M., Krebbers, G., Tjin, E. P. M., Willemsen, K. J., Louis, A., Konijn, V. A. L., Narayan, V. S., Post, N. F., Bakker, W. J., Melief, C. J. M., et al. (2021) · Experimental Dermatology · doi:10.1111/exd.14500 · Cited by 20
Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis
Xu, Y., Jiang, Z., Kuang, X., Chen, X., & Liu, H. (2022) · Journal of Medical Internet Research · doi:10.2196/32728 · Cited by 20
Lo, J. W., Schroeder, J.-H., Beattie, G., Roberts, L. B., Cozzetto, D., Omer, O., Ross, E. M., Heuts, F. W. H., Jowett, G. M., Read, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51719-6 · Cited by 21
Managing Immune-Related Adverse Events to Ipilimumab: A Nurse's Guide
Rubin, K. M. (2012) · Clinical journal of oncology nursing · doi:10.1188/12.cjon.e69-e75 · Cited by 20
Evolving Concepts: Immunity in Oncology from Targets to Treatments
Khan, H., Gucalp, R. A., & Shapira, I. (2015) · Journal of Oncology · doi:10.1155/2015/847383 · Cited by 20
Gunturu, K. S., Meehan, K. R., MacKenzie, T. A., Crocenzi, T. S., McDermott, D. F., Usherwood, E. J., Margolin, K. A., Crosby, N. A., Atkins, M. B., Turk, M. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8153 · Cited by 20
Hirao, L. A., Hokey, D. A., Morrow, M. P., Jure‐Kunkel, M., & Weiner, D. B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024250 · Cited by 20
Rossi, G. R., Mautino, M. R., Awwad, D. Z., Husske, K., Lejukole, H., Koenigsfeld, M., Ramsey, W. J., Vahanian, N. N., & Link, C. J. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31817d2f45 · Cited by 20
Advances and perspectives in immunotherapy of melanoma
Schadendorf, D., Vaübel, J., Livingstone, E., & Zimmer, L. (2012) · Annals of Oncology · doi:10.1093/annonc/mds321 · Cited by 20
Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis
Arriola, E., Wheater, M. J., Lopez, M. A., Thomas, G. J., & Ottensmeier, C. H. H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1209615 · Cited by 20
Waight, J. D., Gombos, R. B., & Wilson, N. S. (2017) · Human Antibodies · doi:10.3233/hab-160308 · Cited by 20
Endocrine dysfunction following immune checkpoint inhibitor therapy
Konda, B., Nabhan, F. A., & Shah, M. H. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000357 · Cited by 20
Tanaka, S., Kushimoto, M., Nishizawa, T., Takubo, M., Mitsuke, K., Ikeda, J., Fujishiro, M., Ogawa, K., Tsujino, I., Suzuki, Y., et al. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0092-9 · Cited by 20
Antigen folding improves loading efficiency and antitumor efficacy of PC7A nanoparticle vaccine
Wilhelm, J., Quiñones-Pérez, M., Wang, J., Wang, X., Basava, V. S., & Gao, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.056 · Cited by 20
Metadata
- Authors
- Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., Morton, K. E., Mavroukakis, S. A., Duray, P. H., Steinberg, S. M., Allison, J. P., Davis, T. A., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- Surgery Branch, Laboratory of Pathology, and Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; Howard Hughes Medical Institute, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720; and Medarex, Inc., Princeton, NJ 08540
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-06-25
- Volume
- 100
- Issue
- 14
- Pages
- 8372-8377
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC166236
- OpenAlex
- W2134638467
- Cited by
- 1,575
- References
- 38
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 26 · 2023: 41 · 2022: 48 · 2021: 52 · 2020: 58 · 2019: 56 · 2018: 68 · 2017: 82 · 2016: 58 · 2015: 72 · 2014: 70 · 2013: 78 · 2012: 72
- FWCI
- 46.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (Z99 CA999999)
- National Cancer Institute (Z01BC010763)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CTLA-4 blockade, metastatic melanoma, autoimmunity, tumor regression, anti-CTLA-4 antibody, HLA-A*0201, cancer immunotherapy, self-tolerance, regulatory T cells, T cell activation, enterocolitis, hypophysitis, hepatitis, skin inflammation
- MeSH terms
- Adult, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colitis, Dermatitis, Female, Humans, Immune Tolerance, Immunotherapy, Injections, Intravenous, Injections, Subcutaneous, Lymphocyte Activation, Male, Melanoma, Membrane Glycoproteins, Middle Aged, Neoplasm Metastasis, Neoplasm Proteins, Peptide Fragments, Peptides, T-Lymphocytes, Cytotoxic, Vaccination, Vitiligo, Antigens, CD, HLA-A2 Antigen, T-Lymphocyte Subsets, Salvage Therapy, Hepatitis, Autoimmune, gp100 Melanoma Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review